Metabolites of progesterone in pregnancy: Associations with perinatal anxiety.

TitleMetabolites of progesterone in pregnancy: Associations with perinatal anxiety.
Publication TypeJournal Article
Year of Publication2023
AuthorsEtyemez S, Miller KN, Voegtline KM, Özdemir İ, Standeven LR, Santovito LSpiro, Pinna G, Payne JL, Osborne LM
JournalPsychoneuroendocrinology
Volume156
Pagination106327
Date Published2023 Oct
ISSN1873-3360
Keywords5-alpha-Dihydroprogesterone, Anxiety Disorders, Cross-Sectional Studies, Female, Humans, Neurosteroids, Pregnancy, Pregnanolone, Progesterone
Abstract

BACKGROUND: Anxiety disorders are the most common psychiatric disorder during the perinatal period and one of the major risk factors for postpartum depression, yet we know little about biological factors in the etiology of perinatal anxiety. A growing literature points to neuroactive steroid (NAS) dysregulation in perinatal mental illness, but directionality has not been clearly demonstrated, results are not consistent, and no studies have investigated NAS in a population with pure anxiety without comorbid depression. We aimed to add to the limited literature by examining the association between anxiety without comorbid depression and metabolic pathways of NAS longitudinally across the peripartum.

METHODS: We measured anxiety symptoms by psychological scales and NAS levels using Gas Chromatography-Mass Spectrometry (GC-MS) at the second and third trimester (T2 and T3) and week 6 postpartum (W6) in n = 36 women with anxiety and n = 38 healthy controls. The anxiety group was determined by a data-driven approach, and cross-sectional and longitudinal statistical methods were used to examine the relationship between the study population and NAS.

RESULTS: We found that anxiety had a significant moderating effect on the relationship between progesterone and allopregnanolone, with no such effect for the relationships between progesterone and the intermediate (5α-DHP) or isomeric (isoallopregnanolone) compounds in this pathway, and no effects on the corresponding pathway converting progesterone to pregnanolone and epipregnanolone. We also found a less precipitous decline in the ratio of allopregnanolone to progesterone between T3 and W6 in the anxiety group compared to the non-anxiety group. A genotype analysis of a single-nucleotide polymorphism in the AKR1C2 gene demonstrated that the relationship of allopregnanolone to the intermediate metabolite, 5α-DHP, differed by genotype.

CONCLUSION: Our exploratory findings indicate that, for pregnant people with anxiety, metabolism is shunted more aggressively toward the endpoint of the progesterone to allopregnanolone metabolic pathway than it is for those without anxiety.

DOI10.1016/j.psyneuen.2023.106327
Alternate JournalPsychoneuroendocrinology
PubMed ID37423029
PubMed Central IDPMC10530426
Grant ListK12 HD085845 / HD / NICHD NIH HHS / United States
K23 MH110607 / MH / NIMH NIH HHS / United States